Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33892 AMC ENTERTAINMENT HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State o ...

Results for the Second Quarter of 2025 and Future Outlook: OMAHA, Neb., Aug 11, 2025 (BUSINESS WIRE) - Green Plains Inc. (NASDAQ:GPRE) ("Green Plains" or the "company") today announced financial results for the second quarter of 2025. Net loss attributable to the company was $72.2 million, or $(1.09) per diluted share, compared to net loss attributable to the company of $24.4 million, or ($0.38) per diluted share, for the same period in 2024. The results for the quarter include $44.9 million in non-cash cha ...

Exhibit 99.1 INVESTOR RELATIONS: John Merriwether, 866-248-3872 InvestorRelations@amctheatres.com MEDIA CONTACTS: Ryan Noonan, (913) 213-2183 rnoonan@amctheatres.com so doing, we have put in place a solid foundation to capitalize on what we believe will be our industry's continued growth momentum, especially evident in the fourth quarter of 2025 and continuing deep into 2026." FOR IMMEDIATE RELEASE AMC Entertainment Holdings, Inc. Reports Second Quarter 2025 Results LEAWOOD, KANSAS - (August 11, 2025) -- AM ...

Press Release Excelerate Energy Reports Strong Second Quarter 2025 Results and Raises Full- Year Guidance The Woodlands, TX, August 11, 2025 – Excelerate Energy, Inc. (NYSE: EE) ("Excelerate" or the "Company") today reported its financial results for the second quarter ended June 30, 2025. RECENT HIGHLIGHTS CEO COMMENT Net income for the second quarter of 2025 decreased sequentially from the last quarter due to transition and transaction costs incurred as a result of the Jamaica acquisition. Net income and ...

Exhibit 99.1 Owens & Minor Reports Second Quarter 2025 Financial Results Classified Products & Healthcare Services Segment as Discontinued Operations Continuing Operations, Patient Direct, Showed Solid Performance and Growth RICHMOND, VA – August 11, 2025 – Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the second quarter ended June 30, 2025. In connection with a likely sale of the Company's Products & Healthcare Services segment, the results herein, unless otherwise noted, reflect the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 | _________________________ | | | --- | --- | | Evolent Health, Inc. ( ...

Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA and Revises Upwards 2025 Financial Guidance Ranges LOS ANGELES, California, August 11, 2025 – RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost- effective, fixed-site outpatient diagnostic imaging services through a network of 405 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2025. Dr. How ...

PART I. FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20%28Unaudited%29) The unaudited financial statements for the period ended June 30, 2025, show decreased cash and total assets, an increased net loss of $7.5 million, and higher cash used in operations [Balance Sheets](index=4&type=section&id=Balance%20Sheets) As of June 30, 2025, total assets decreased to **$6.0 million** from **$10.1 million**, driven by reduced cash, with liabilities and equity also falling Balance Sheet Summary (Unaudited) | Account | June 30, 2025 ($M) | December 31, 2024 ($M) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $5.57M | $10.02M | | Total current assets | $5.97M | $10.11M | | **Total assets** | **$5.98M** | **$10.12M** | | **Liabilities & Equity** | | | | Total current liabilities | $1.68M | $2.68M | | **Total liabilities** | **$1.68M** | **$2.68M** | | Accumulated deficit | $(33.24M) | $(25.72M) | | **Total stockholders' equity** | **$4.30M** | **$7.44M** | [Statements of Operations and Comprehensive Loss](index=5&type=section&id=Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss for the six months ended June 30, 2025, increased to **$7.5 million**, driven by higher operating expenses, particularly General and Administrative costs Operating Results (Unaudited) | Metric | Three Months Ended June 30, 2025 ($M) | Three Months Ended June 30, 2024 ($M) | Six Months Ended June 30, 2025 ($M) | Six Months Ended June 30, 2024 ($M) | | :--- | :--- | :--- | :--- | :--- | | General and administrative expenses | $2.66M | $1.21M | $4.91M | $2.34M | | Research and development expenses | $1.08M | $1.25M | $2.75M | $1.88M | | **Loss from operations** | **$(3.73M)** | **$(2.47M)** | **$(7.66M)** | **$(4.22M)** | | **Net loss** | **$(3.67M)** | **$(2.39M)** | **$(7.51M)** | **$(4.06M)** | | **Net loss per share (basic and diluted)** | **$(1.87)** | **$(2.24)** | **$(3.95)** | **$(3.80)** | [Statements of Cash Flows](index=7&type=section&id=Statements%20of%20Cash%20Flows) Net cash used in operating activities more than doubled to **$7.7 million** for the six months ended June 30, 2025, resulting in a **$4.4 million** net decrease in cash Cash Flow Summary (Unaudited) | Cash Flow Activity | Six Months Ended June 30, 2025 ($) | Six Months Ended June 30, 2024 ($) | | :--- | :--- | :--- | | Net cash used in operating activities | $(7,674,557) | $(3,365,624) | | Net cash used in investing activities | $(3,251) | $0 | | Net cash provided by financing activities | $3,230,596 | $298 | | **Net change in cash and cash equivalents** | **$(4,447,212)** | **$(3,365,326)** | | **Cash and cash equivalents – end of period** | **$5,570,730** | **$5,037,174** | [Notes to Financial Statements](index=8&type=section&id=Notes%20to%20Financial%20Statements) Notes highlight tecarfarin development, going concern uncertainty, a **1-for-15 reverse stock split**, and recent ATM equity sales - The company is a biopharmaceutical firm developing **tecarfarin**, a novel oral anticoagulant, for cardiovascular conditions like **end-stage kidney disease with atrial fibrillation (ESKD+AFib)** and for patients with **left ventricular assist devices (LVADs)**[21](index=21&type=chunk)[22](index=22&type=chunk) - The company's cash balance of approximately **$5.0 million** as of August 6, 2025, is expected to fund operations for at least the **next twelve months**[27](index=27&type=chunk) However, **additional funding** is necessary for further late-stage clinical trials, including a **Phase 3 trial** for tecarfarin[28](index=28&type=chunk) - A **1-for-15 reverse stock split** was effected on August 20, 2024[63](index=63&type=chunk) All share and per-share data have been retroactively adjusted to reflect this split[63](index=63&type=chunk) - During the six months ended June 30, 2025, the company sold **186,294 shares** through its **at-the-market (ATM) facility**, generating net proceeds of approximately **$3.2 million**[73](index=73&type=chunk) - Subsequent to the quarter end, from July 1 to July 14, 2025, the company sold an additional **39,741 shares** via its **ATM facility**, raising net proceeds of approximately **$499,000**[90](index=90&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management focuses on tecarfarin for niche cardiovascular conditions; H1 2025 operating expenses increased, requiring additional capital for future clinical trials - The company is pursuing a 'pipeline-in-a-product' approach for **tecarfarin**, targeting niche cardiovascular conditions where DOACs have failed or are unproven, such as in patients with **ESKD and AFib**, or those with **LVADs**[97](index=97&type=chunk)[98](index=98&type=chunk) - On **August 5, 2025**, the company announced plans to initiate a **clinical trial** for tecarfarin in patients with **ESKD transitioning to dialysis**, with enrollment expected to begin later in the year[100](index=100&type=chunk) - As of August 11, 2025, the company had approximately **$5.0 million** in cash and cash equivalents, which is expected to fund operations for at least the **next twelve months**[113](index=113&type=chunk) However, **additional funding** is needed for any further clinical trials, including a **Phase 3 trial** for tecarfarin[113](index=113&type=chunk) [Results of Operations](index=22&type=section&id=Results%20of%20Operations) Total operating expenses increased to **$7.7 million** for the six months ended June 30, 2025, driven by significant increases in G&A and R&D Comparison of Operating Expenses (Six Months Ended June 30) | Expense Category | 2025 ($) | 2024 ($) | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | General and administrative | $4,910,970 | $2,338,430 | $2,572,540 | 110% | | Research and development | $2,745,379 | $1,882,736 | $862,643 | 46% | | **Total operating expenses** | **$7,662,267** | **$4,222,233** | **$3,440,034** | **81.5%** | - The **$2.6 million** increase in G&A expenses for the six-month period was primarily due to a **$1.3 million** rise in public company costs, a **$0.6 million** increase in stock-based compensation, and a **$0.2 million** increase in personnel-related expenses[110](index=110&type=chunk) - The **$0.9 million** increase in R&D expenses for the six-month period was mainly attributed to a **$0.5 million** increase in CMC expenses, a **$0.3 million** increase in personnel costs (severance), and a **$0.1 million** increase in clinical trial preparation costs[111](index=111&type=chunk) [Liquidity and Capital Resources](index=24&type=section&id=Liquidity%20and%20Capital%20Resources) The company funds operations through equity sales; cash used in operations increased to **$7.7 million** in H1 2025, partially offset by **$3.2 million** from financing Cash Flow Summary (Six Months Ended June 30) | Activity | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | Cash used in operating activities | $(7,674,557) | $(3,365,624) | | Cash provided by financing activities | $3,230,596 | $298 | | **Net change in cash** | **$(4,447,212)** | **$(3,365,326)** | - Cash used in operating activities for the first six months of 2025 was **$7.7 million**, driven by a net loss of **$7.5 million** (which included **$1.1 million** of non-cash expenses) and a **$1.3 million** use of cash from changes in operating assets and liabilities[113](index=113&type=chunk)[115](index=115&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=25&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section is not applicable as the company qualifies as a smaller reporting company - The company is a **smaller reporting company** and is not required to provide these disclosures[121](index=121&type=chunk) [Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting - Based on an evaluation as of June 30, 2025, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were **effective** at the **reasonable assurance level**[123](index=123&type=chunk) - **No changes** in internal control over financial reporting occurred during the quarter ended June 30, 2025, that have **materially affected**, or are reasonably likely to materially affect, internal controls[124](index=124&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=27&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently subject to any material legal proceedings - The company is **not currently a party** to any **material legal proceedings**[126](index=126&type=chunk) [Risk Factors](index=27&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report - There have been **no material changes** from the risk factors disclosed in the company's Annual Report[127](index=127&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=27&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) On June 29, 2025, the company issued **10,000 shares** of restricted common stock to a consultant, exempt from registration under Section 4(a)(2) - On **June 29, 2025**, the company issued **10,000 shares** of **restricted common stock** to a consultant for services, exempt from registration under **Section 4(a)(2) of the Securities Act**[129](index=129&type=chunk) [Other Information](index=27&type=section&id=Item%205.%20Other%20Information) On May 9, 2025, the CEO and CFO entered into Rule 10b5-1 stock selling plans for up to **50,600** and **33,333 shares**, effective August 2025 - On **May 9, 2025**, the CEO and CFO entered into **Rule 10b5-1 stock selling plans**[135](index=135&type=chunk) - The plans allow for the sale of a maximum of **50,600 shares** by the CEO and **33,333 shares** by the CFO, with the selling period beginning in **August 2025** and ending in **November 2025**[136](index=136&type=chunk) [Exhibits](index=28&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed or furnished as part of the Quarterly Report on Form 10-Q - The report includes an **Exhibit Index** listing all documents filed or furnished with the **Form 10-Q**[137](index=137&type=chunk)

Exhibit 99.1 Rumble Reports Second Quarter 2025 Results ~ Revenue up 12% Year-over-Year to $25.1 Million ~ ~ Quarter Concluded with Class A Shares Being Added to Russell 2000 & 3000 ~ ~ ARPU of $0.42, Up 24% from Prior Quarter ~ LONGBOAT KEY, Fla., August 10, 2025 (GLOBE NEWSWIRE) -- Rumble Inc. (Nasdaq: RUM) ("Rumble" or the "Company"), the video-sharing platform and cloud services provider, today announced financial results for the fiscal quarter ended June 30, 2025. Q2 2025 Key Highlights and Key Items ● ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _________________ Commission file number 001-37762 Yum China Holdings, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or O ...